Tumour Lysis Syndrome and Partial Remission Occurring After Administration of a Test Dose of Obinutuzumab
  • Mohamad Jaffer Abdalkhalig Mustafa
    Department of Haematology, Galway University Hospital, Galway
  • Mohamed Bakri Mohamed
    Department of Haematology, Galway University Hospital, Galway
  • Amjad Hayat
    Department of Haematology, Galway University Hospital, Galway

Keywords

Chronic lymphocytic leukaemia, Obinutuzumab, tumour lysis syndrome

Abstract

Chronic lymphocytic leukaemia (CLL) is one of the most common haematological malignancies worldwide, with an increasing prevalence in the elderly population. Obinutuzumab is a type II anti-CD20 monoclonal antibody which showed superiority over rituximab in combination chemotherapy with chlorambucil for the treatment of CLL in the CLL11 trial (NCT01010061) and is becoming part of standard first line treatment for CLL in the elderly based on its potent efficacy and benign safety profile. We report the case of a chemotherapy naive patient who develop tumour lysis syndrome despite appropriate prophylaxis, and had partial remission of her disease after receiving only the initial test dose of obinutuzumab.

VIEW THE ENTIRE ARTICLE

References

  • Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014;370:1101–1110.
  • Kern DJ, James BR, Blackwell S, Gassner C, Klein C, Weiner GJ. GA101 induces NK-cell activation and antibody-dependent cellular cytotoxicity more effectively than rituximab when complement is present. Leuk Lymphoma 2014;54:2500–2505.
  • Klein C, Lammens A, Schäfer W, Georges G, Schwaiger M, Mössner E, et al. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. MAbs 2013;5:22–33.
  • Byrd JC, Flynn JM, Kipps TJ, Boxer M, Kolibaba KS, Carlile DJ, et al. Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia. Blood 2016;127:79–86.

    • Views: 1120
    HTML downloads: 301
    PDF downloads: 519

    Published: 2017-01-27
    Issue: Vol. 4 No. 1 (view)

    How to cite:
    1.
    Mustafa MJA, Mohamed MB, Hayat A. Tumour Lysis Syndrome and Partial Remission Occurring After Administration of a Test Dose of Obinutuzumab. EJCRIM 2017;4 doi:10.12890/2016_000516.